Rick Doblin — Psychedelic Breakthroughs, $10M Bets, PTSD Promise, and More | The Tim Ferriss Show

Tim Ferriss interviews Rick Doblin about the history, science, and clinical promise of MDMA-assisted psychotherapy for PTSD. Doblin traces MDMA from its origins at Merck and the underground therapy movement through the DEA's 1984 criminalization and his founding of MAPS to bring it through the FDA. He explains how MDMA reduces amygdala fear response and enables memory reconsolidation, allowing trauma survivors to process buried experiences in just two to three sessions with lasting effects. The conversation features the foundational 1984 case of a suicidal rape survivor named Marcela and the veteran Jonathan Lubecky, alongside the underlying neuroscience and integration work. The episode closes with the announcement of a $10 million challenge grant within a $30 million capstone fund to fund the Phase 3 trials and get MDMA approved.

• In MAPS Phase 2 trials of 107 participants, 56% no longer qualified for PTSD two months after MDMA-assisted psychotherapy, rising to 68% at 12-month follow-up, after just two to three sessions.
  00:09:31
• Doblin describes the foundational 1984 case of Marcela, a suicidal date-rape survivor he treated in his home with MDMA and an LSD/MDMA session, who recovered and later became a lead MAPS therapist and trainer.
  00:39:46
• The lasting change comes from two factors: the drug experience rewires the brain via oxytocin-driven new neural connections plus fear extinction and memory reconsolidation, combined with non-drug integration psychotherapy afterward.
  00:31:54
• MAPS and PSFC launched a $30 million capstone fund to get MDMA across the finish line, with ~$10 million already raised internally.
  01:07:29
• Tim Ferriss and others (Peter Rahal, James Bailey, Blake Mycoskie, the Steven and Alexandra Cohen Foundation) committed a $10 million challenge grant that activates if another $10 million is raised within 90 days.
  01:08:31
• For Phase 3, MAPS moved star therapists Michael and Annie Mithoefer into training roles, and roughly 70 new therapists, many of whom had never done MDMA, achieved comparable results, demonstrating scalability.
  01:22:05
• MAPS' interim analysis showed at least a 90% probability of statistical significance with no need to add participants, and an FDA agreement letter legally binds the FDA to approve if efficacy is shown without new safety problems.
  01:20:32

• All Phase 2 participants had chronic treatment-resistant PTSD, having suffered for an average of 17.8 years.
  00:10:35
• MDMA was invented by Merck in 1912 while trying to evade a competitor's patent, and the company did essentially nothing with it for 15 years.
  00:10:35
• The 1953 US Army chemical warfare service tested MDMA as a potential mind-control drug; it sits chemically about halfway between methamphetamine and mescaline.
  00:11:51
• MDMA was a therapy drug used by psychiatrists (about half a million doses) before it became the party drug ecstasy, flourishing at the Starck Club in Dallas.
  00:16:12
• Neuroscientist Gul Dolen found octopuses, which diverged from humans ~550 million years ago, become pro-social on MDMA, and her Nature mouse study showed oxytocin stimulates new neural connections.
  00:32:25
• LSD was the first psychedelic used to treat PTSD, by Dutch psychiatrist Bastiaans after WWII for what he called concentration camp syndrome in Holocaust survivors and resistance fighters.
  00:48:35
• MAPS expects to spend roughly $65 million on Phase 3 versus an industry median of hundreds of millions to over $2 billion per drug, having reviewed over 5,000 existing MDMA/ecstasy papers worth about $450 million.
  01:17:26
• Only two drugs received FDA breakthrough therapy designation for PTSD; the competitor (Tonix's repurposed sleeping pill) failed for futility after spending over $100 million.
  01:19:30
• The VA spends an estimated $15-20 billion a year on PTSD disability payments yet has given MAPS no funding, and roughly 20 veterans die by suicide per day in the US.
  01:27:48
• Doblin recounts two women with nearly identical rave experiences months apart: the one who suppressed surfaced memories felt worse, while the one who processed them with a friend felt better, illustrating that response matters more than the substance.
  00:58:29